Chardan downgraded Cargo Therapeutics (CRGX) to Neutral from Buy without a price target The company will be discontinuing the Phase II FIRCE-1 ...

Fintel reports that on January 30, 2025, Chardan Capital downgraded their outlook for CARGO Therapeutics (NasdaqGS:CRGX) from ...

CARGO Therapeutics (NASDAQ:CRGX – Get Free Report) was downgraded by stock analysts at Chardan Capital from a “buy” rating to ...

In a challenging market environment, shares of Chardan Nextech Acquisition 2 (DFLI) have reached a 52-week low, dipping to $2.13. The company, which has been navigating through a turbulent financial ...

Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

Chardan analyst Geulah Livshits downgraded Editas Medicine (EDIT) to Neutral from Buy and withdrew the firm’s price target after the company announced a strategic transition to focus entirely on ...

Chardan downgraded CervoMed (CRVO) to Neutral from Buy without a price target after the company announced topline data from the Phase 2b RewinD-LB of neflamapimod, its only clinical stage asset ...

On Thursday, Chardan Capital Markets revised its rating on Cargo Therapeutics (NASDAQ:CRGX) stock from Buy to Neutral, following the company's announcement to halt its phase II FIRCE-1 clinical trial.

With assistance from Chardan, the Company will continue to assess a full range of strategic alternatives, including but not limited to, a business combination, sale of the Company, reverse merger ...

CARGO Therapeutics, Inc. (CRGX – Research Report) received a Hold rating and price target from Chardan Capital analyst Geulah Livshits ...

On Thursday, Chardan Capital Markets revised its rating on Cargo Therapeutics (NASDAQ:CRGX) stock from Buy to Neutral, following the company's announcement to halt its phase II FIRCE-1 clinical trial.